Passage Bio - PASG Net earnings per share (EPS TTM)

Official company branding of Passage Bio Inc. (PASG)

Passage Bio, Inc. (PASG) is developing neurogenic therapy in collaboration with the University of Pennsylvania, accelerating global trials. The business's success relies on regulatory approval and interest from pharmaceutical behemoths. The implementation of robotic laboratories optimizes data validation. The YoY percentage change in EPS over 12 months on the GURU.Markets chart reflects profit dynamics, where 28.20 determines the current value of the indicator.

Net earnings per share (EPS TTM): Passage Bio Corp (PASG) for 02/11/2024 - 11/13/2026

Passage Bio Corp - analytical breakdowns and key metrics (PASG)

- market price and analyst price targets:
Market Chart Passage Bio, Inc.|PASG - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Passage Bio Inc.|PASG - Enterprise Value
- shareholders' equity book value data:
Book Value of One Share Passage Bio|PASG - Book Capitalization|Market-to-Book Ratio passagebio.com|PASG - Cumulative Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Passage Bio, Inc.|PASG - Long-Term Debt to Capital|Short-Term Debt to Equity Passage Bio, Inc.|PASG - Company Aggregate Debts|Debts to Net Assets Passage Bio Inc.|PASG - Company Long-Term Debt|Short-Term Debt Passage Bio|Intermediate Coverage Ratio passagebio.com
- company profitability and valuation multiples indicators:
PASG - Net Profit|Company Profit Forecast Passage Bio, Inc.|PASG - Price to Earnings Ratio|Price to Future Earnings Ratio Passage Bio, Inc.|PASG - PEG Multiple|Enterprise Value to EBITDA Ratio Passage Bio Inc.|PASG - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Passage Bio|PASG - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months passagebio.com|PASG - Earnings growth in current year|Earnings growth forecast for next year Passage Bio, Inc.
Fundamental company valuation:PASG (Passage Bio)
Product sample of Passage Bio, Inc.

For investors, assessing the sustainability of the Passage Bio (PASG) business model is critical during a period of strict R&D portfolio prioritization and management cost optimization. Analyzing the year-over-year EPS trend (over 12 months) allows for the measurement of the actual rate of change in net profit per share, revealing the company's ability to generate value per share amid external shocks and the anticipation of clinical data.

Competitor analysis

Net earnings per share for the last four quarters biogen.com BIIB|NBIX: Net earnings per share (EPS TTM)|Regencell Bioscience Ltd (RGC) - Net earnings per share (EPS TTM)|AXSM (Axsome Therapeutics Inc) - Net earnings per share (EPS TTM)|ACAD - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) XENE|VKTX - Net earnings per one share for the last twelve months|Supernus - Net earnings per share for the last 12 months|Earnings per share for the trailing year CPRX|Denali Therapeutics Inc - Net earnings per share (EPS TTM)|HRMY: Earnings per share for the last twelve months|BHVN: Net earnings per share (EPS TTM)|AMLX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Trevi Therapeutics, Inc.|Net earnings per one share for the last twelve months Praxis Precision Medicines Inc PRAX|Net earnings per share for the last 12 months AVXL (Anavex Corp)|CBLL (CeriBell EEG) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) PRTA (Prothena Corporation)|Net earnings per share for the last four quarters Alector Inc. (ALEC)|ANNX - Earnings per share for the last twelve months|OMER (Omeros Corporation) - Earnings per share for the last 12 months|NGNE: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months AC Immune Inc|Net earnings per share for the last 12 months VYGR|neumoratx.com (NMRA) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Scilex (SCLX)|TVGN: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) ACOG (Alpha Cognition Inc.)|Net earnings per share (EPS TTM) cogrx.com CGTX|IKT - Earnings per share for the last twelve months|Net earnings per share for the last four quarters cassavasciences.com SAVA|ASRT: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Coya Therapeutics COYA|Earnings per share for the last twelve months VistaGen Therapeutics, Inc.|Earnings per share for the last 12 months OVID (Ovid Rx)|Net earnings per share (EPS TTM) ABOS|CRVO - Net earnings per one share for the last twelve months|Alterity Therapeutics Limited - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Clene Inc CLNN|PEPG - Earnings per share for the last twelve months|Earnings per share for the trailing year JUNS (jupiterneurosciences.com)|Relmada Therapeutics (RLMD) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months annovisbio.com (ANVS)|Earnings per share for the last twelve months Grace Therapeutics Inc|Firefly Neuroscience, Inc. - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) KLTO|Net earnings per share (EPS TTM) neurosense-tx.com (NRSN)|Earnings per share for the last twelve months Reviva Pharmaceuticals RVPH|Net earnings per share for the last four quarters MetaVia Inc. (MTVA)|NRXS - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Helius Medical HSDT|NEUP: Net earnings per share (EPS TTM)|Minerva (NERV) - Net earnings per share (EPS TTM)|ATHA (Athira Pharma, Inc.) - Net earnings per share (EPS TTM)|ADXN - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) ALZN|CYCN - Net earnings per one share for the last twelve months|Protagenic Therapeutics, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year KTTA|Cortigent Medical - Net earnings per share (EPS TTM)|ATXI: Earnings per share for the last twelve months|BCLI: Net earnings per share (EPS TTM)|CARA - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Chromocell Therapeutics Corporation|Net earnings per one share for the last twelve months Eliem ELYM|Net earnings per share for the last 12 months ITCI (Intra-Cellular Therapies)|LBPH (longboardpharma.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) MRNS (Marinus Pharmaceuticals, Inc.)|Net earnings per share for the last four quarters NKGen Biotech Inc (NKGN)|NRBO - Earnings per share for the last twelve months|SAGE (Sage Therapeutics Inc) - Earnings per share for the last 12 months|SNPX: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months trevena.com|Net earnings per share for the last 12 months VIGL|Anew Medical Inc. (WENA) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Cerevel (CERE)